Royalty Report: Drugs, Pharmaceuticals, Disease – Collection: 3321


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Disease
  • Pain
  • Parkinsons Disease
  • Medical
  • Therapeutic
  • Receptors
  • Central Nervous System

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3321

License Grant
The Licensee licensed its Captisol-enabled Lamotrigine program to the Licensee.
License Property
Lamotrigine is an anticonvulsive used in treatment of certain forms of epilepsy.
Field of Use
The Licensee is developing the product for CNS (central nervous system) indications and is responsible for all development costs relating to the program.

IPSCIO Record ID: 2436

License Grant
The Company licensing right to the Products used in connection with Lamotrigine (Lamictal).
License Property
Lamotrigine is an anticonvulsant that is chemically unrelated to any other anticonvulsant or mood regulating medication.
Field of Use
This medication works with other medications to help control seizure disorders.

IPSCIO Record ID: 108273

License Grant
The Licensor announces the licensing of rights to four programs to the  privately-held Licensee.
License Property
The Programs are Aplindore Program,  Aplindore Program (all other licensed products),  Captisol-enabledâ„¢ Acetaminophen Program,  CRTh2 Antagonist Program,  H3 Receptor Program.

Aplindore for  Parkinson's disease and restless legs syndrome.  Captisol-enabledâ„¢ Acetaminophen Program for Pain and Fever.
CRTh2 Antagonist Program for respiratory disorders.  H3 Receptor Program for Narcolepsy.

Field of Use
The Licensee is a biopharmaceutical company focused on central nervous system (CNS), respiratory and other disorders.

IPSCIO Record ID: 60411

License Grant
The parties have an agreement regarding the development of Captisol-enabled therapeutics.
License Property
Captisol-enabled SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors that is in clinical development as an adjunctive therapy, a therapy combined with current therapeutic approaches, for the treatment of Super-refractory status epilepticus (SRSE).   SAGE-547 was granted Fast Track designation, which is intended to facilitate the development and expedite the review of drug candidates that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs, and orphan drug designation, which is intended to facilitate drug development for rare diseases, by the FDA for SRSE.
Field of Use
Licensee is conducting a Phase 3 clinical trial for the development of Captisol-enabled therapeutics for a broad range of debilitating central nervous system conditions.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.